SECURITIES AND EXCHANGE COMMISSION

                              WASHINGTON, DC 20549


                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                                JANUARY 10, 2006

                                 Date of Report
                        (Date of earliest event reported)

                       NEW BRUNSWICK SCIENTIFIC CO., INC.

               (Exact Name of Registrant as Specified in Charter)

     NEW JERSEY                    0-6994                    22-1630072
State or Other
Jurisdiction of          (Commission File Number)          (IRS Employer
Incorporation)                                             Identification No.)


          44 TALMADGE ROAD, EDISON, NJ                         08818-4005
       (Address of Principal Executive Offices)                    (ZIP Code)


          Registrant's telephone number, including area code:  (732) 287-1200

          (Former Name or Former Address, if Changed Since Last Report)







1

Item 5.02     Appointment of Principal Officers

                       NEW BRUNSWICK SCIENTIFIC CO., INC.
           P.O. Box 4005 - 44 Talmadge Road - Edison, NJ 08818-4005 U.S.A.




CONTACTS:

James Orcutt                            Matthew J. Dennis, CFA
President & Chief Operating Officer     NBS Investor Relations
New Brunswick Scientific Co., Inc.      Clear Perspective Group, LLC
732.650.2525                            440.353.0552
jorcutt@nbsc.com                        mdennis@cpg-llc.com


FOR IMMEDIATE RELEASE


           NEW BRUNSWICK SCIENTIFIC NAMES NEW CHIEF FINANCIAL OFFICER


EDISON,  NEW  JERSEY,  JANUARY 10, 2006-New Brunswick Scientific Co., Inc. (NBS)
(NASDAQ: NBSC), a leading provider of a comprehensive line of research equipment
and  scientific  instrumentation  for  use  in  the life science industry, today
announced  that  Thomas  E.  Bocchino,  46,  has  been appointed vice president,
Finance  and  chief  financial  officer,  replacing  Samuel  Eichenbaum  who, as
previously  announced,  will  retire  as  an  employee  of the company effective
January  31,  2006.

For  the past five years, Bocchino was chief financial officer of IVC Industries
Inc.,  now  a  subsidiary  of  Inverness  Medical  Innovations,  Inc.,  with
responsibilities  for  financial  reporting, internal control and Sarbanes-Oxley
compliance.  He  served  as  IVC's  controller  from  1990  to  1997.

Prior  to  joining IVC, Bocchino gained industry experience through increasingly
responsible  positions  with  Rheem Manufacturing Co.'s Container Division, Jazz
Photo  Corp.  and in public accounting. Bocchino earned his bachelor's degree in
Business Administration from the University of Dayton.  He is a Certified Public
Accountant  in  the  State  of  New  Jersey.

Commenting  on  the new hire, NBS co-founder and Chairman David Freedman stated,
"We  are  pleased  to  welcome  Tom  to  our  company  and  look  forward to his
contribution  toward achievement of our strategic objectives and the enhancement
of  shareholder  value.

2

"We  also  would like to take this opportunity to commend Sam Eichenbaum for his
21 years of dedicated service to our company, and wish him much happiness in his
retirement."

To be added to New Brunswick Scientific's e-mail distribution list, please click
on  the  link  below:

http://www.clearperspectivegroup.com/clearsite/nbsc/emailoptin.html
- -------------------------------------------------------------------

ABOUT NEW BRUNSWICK SCIENTIFIC
New  Brunswick  Scientific  Co.,  Inc.,  is  a  leading  global  provider  of  a
comprehensive  line of research equipment and scientific instrumentation for use
in  the  life science industry. The Company's products are used in the creation,
maintenance  and  control  of physical and biochemical environments required for
the  growth, detection and storage of microorganisms for medical, biological and
chemical  applications, as well as environmental research and commercial product
development.  NBS  is a forerunner in the research and development of pioneering
equipment  to  meet  the challenges of new areas of advancement in life science.
Established  in  1946,  New Brunswick Scientific is headquartered in Edison, New
Jersey,  with  sales  and  distribution  facilities strategically located in the
United  States, Europe and Asia. For more information, please visit www.nbsc.com
                                                                   ------------.


This  press  release contains "forward-looking statements" within the meaning of
the  Private  Securities  Litigation  Reform  Act  of  1995.  Forward-looking
statements  may  be  identified  by  words  such  as  "expects,"  "anticipates,"
"intends," "plans," "believes," "seeks," "estimates," "will" or words of similar
meaning  and  include,  but  are  not  limited to, statements about the expected
future  business  and  financial performance of the Company. The forward-looking
statements  involve  a  number  of  risks  and  uncertainties, including but not
limited  to:  changes in economic conditions, demand for the Company's products,
pricing  pressures,  intense  competition in the industries in which the Company
operates,  the need for the Company to keep pace with technological developments
and  respond  in  a  timely  manner  to changes in customer needs, the Company's
dependence  on  third-party  suppliers,  the effect on foreign sales of currency
fluctuations, acceptance of new products, the labor relations of the Company and
its  customers  and  other  factors  identified  in the Company's Securities and
Exchange  Commission  filings.  Forward-looking  statements  are  based  on
management's  current expectations and assumptions, which are inherently subject
to  uncertainties,  risks  and  changes  in  circumstances that are difficult to
predict.  Actual  outcomes  and  results  may  differ  materially  from  these
expectations  and  assumptions  due  to  changes  in global political, economic,
business,  competitive,  market,  regulatory  and  other  factors.  The  Company
undertakes  no  obligation  to  publicly  update  or  review any forward-looking
information,  whether  as  a  result  of new information, future developments or
otherwise.



3

                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant had duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                              NEW BRUNSWICK SCIENTIFIC CO., INC.

Date: January 10, 2006                    by:  /s/ David Freedman

- ----------------------------------------------------
                                   David Freedman
                                   Chairman and
                                   Chief Executive Officer

4